Evidence map›Paper›PMID 37938390›Full record

ArticleBioprocess and biosystems engineering2023

Large-scale crystallization as an intermediate processing step in insulin downstream process: explored advantages and identified tool for process intensification.

Partha Hazra, Madhavan Buddha, Chinnappa Reddy, Indranil Gupta

Abstract read
PubMed Publisher
In one paragraph

Article in Bioprocess and biosystems engineering, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 4 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Partha HazraBiocon Biologics Limited (BBL), Biocon Research Center (BRC), Biocon Park, Plot No. 2 & 3, Bommasandra Industrial Estate, IV Phase, Bommasandra Jigani Link Road, Bangalore, 560 099, India. Partha.Hazra@biocon.com.ORCID http://orcid.org/0000-0002-3998-9368
Madhavan BuddhaBiocon Biologics Limited (BBL), Biocon Research Center (BRC), Biocon Park, Plot No. 2 & 3, Bommasandra Industrial Estate, IV Phase, Bommasandra Jigani Link Road, Bangalore, 560 099, India.
Chinnappa ReddyBiocon Biologics Limited (BBL), Biocon Research Center (BRC), Biocon Park, Plot No. 2 & 3, Bommasandra Industrial Estate, IV Phase, Bommasandra Jigani Link Road, Bangalore, 560 099, India.
Indranil GuptaBiocon Biologics Limited (BBL), Biocon Research Center (BRC), Biocon Park, Plot No. 2 & 3, Bommasandra Industrial Estate, IV Phase, Bommasandra Jigani Link Road, Bangalore, 560 099, India.
Biocon (India) · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The rising global prevalence of diabetes and increasing demand for insulin, calls for an increase in accessibility and affordability of insulin drugs through efficient and cost-effective manufacturing processes. Often downstream operations become manufacturing bottlenecks while processing a high volume of product. Thus, process integration and intensification play an important role in reducing process steps and time, volume reduction, and lower equipment footprints, which brings additional process efficiencies and lowers the production cost. Manufacturers thrive to optimize existing unit operation to maximize its benefit replacing with simple but different efficient technologies. In this manuscript, the typical property of insulin in forming the pH-dependent zinc-insulin complex is explored. The benefit of zinc chloride precipitation/crystallization has been shown to increase the in-process product purity by reducing the product and process-related impurities. Incorporation of such unit operation in the insulin process has also a clear potential for replacing the high cost involved capture chromatography step. Same time, the reduction in volume of operation, buffer consumption, equipment footprint, and capabilities of product long time storage brings manufacturing flexibility and efficiencies. The data and capabilities of simple operation captured here would be significantly helpful for insulins and other biosimilar manufacturer to make progresses on cost-effective productions.

Indexed as

ChromatographyInsulinCrystallizationInsulinInsulin downstream processInsulin intermediates crystallizationPichia pastorisProcess intensificationPurification through crystallization

Identifiers

PMID37938390
OpenAlexW4388497941

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.